Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Authors:
Open Access
- 26 March 2022
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Abstract
Background: The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatment remains unclear. This study aimed to evaluate the influence of SMI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC). Methods: We reviewed patients with breast cancer who underwent NAC and subsequent surgery for breast cancer between 2010 and 2017. The rate of SMI change during NAC was calculated, and the association between SMI changes and prognosis was retrospectively analyzed. Results: In total, 141 patients were evaluated. 48 (34.0%), 53 (37.6%), and 40 (28.4%) patients exhibited increased (≥ 3%), maintained (− 3% <, < 3%), and decreased (− 3% ≥) SMI during NAC, respectively. The decreased SMI group showed significantly poorer disease-free survival than the maintained and increased SMI groups (hazard ratio [HR] 8.29, p < 0.001 for the decreased vs. increased SMI groups; HR 3.49, p < 0.001 for the decreased vs. maintained SMI groups). Moreover, decreased SMI was an independent risk factor for disease-free survival in multivariate analysis (HR 3.68, p < 0.01). Conclusions: Skeletal muscle loss during NAC predicts poor prognosis. Our results underscore the importance of monitoring and maintaining skeletal muscle mass during NAC.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal CancerPLOS ONE, 2015
- Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancerActa Oncologica, 2014
- More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of careGastric Cancer, 2014
- Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancerEuropean Radiology, 2014
- Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL StudyJournal of Cancer Survivorship, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling ProjectBreast Cancer Research and Treatment, 2011
- The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophyPflügers Archiv - European Journal of Physiology, 2011
- Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapyCancer Chemotherapy and Pharmacology, 2010
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals of Oncology, 2007